Automatic issuance system of gene test report related to clopidogrel medication

Abstract

The present invention provides an automatic issuing system for clopidogrel medication-related gene detection reports, which covers a lot of information such as patient basic information, test results, test conclusions, and individualized drug recommendations, and can effectively integrate and centrally display a large amount of information. The individualized medication suggestion part can be edited uniformly and applied directly, or individualized remark information can be added separately; even in the case of a large number of detection cases, it can also be based on the relevant genes (CYP 2C19, PON1 and ABCB1) on the genetic testing instrument The genotype results of the clopidogrel medication can be quickly, efficiently and accurately issued a genetic test report related to clopidogrel medication, as long as the basic clinical information and genetic test results of the patient are entered, the test report can be automatically issued. It avoids a lot of manpower consumption when issuing cumbersome reports, can save a lot of time and cost, and can reduce the error rate when issuing reports, so that it is convenient for medical staff to use in clinical work.

Description

technical field [0001] The invention belongs to the technical field of medical information management, in particular to a system for automatically issuing a gene detection report related to clopidogrel medication. Background technique [0002] Clopidogrel is an important antiplatelet drug for the treatment of acute coronary syndrome and percutaneous coronary intervention, but 4% to 30% of patients experience a decline in the efficacy of clopidogrel during treatment, or even clopidogrel resistance (ie, clopidogrel resistance). ineffective after administration). With the rapid development of pharmacogenetics and precision medicine, it has been confirmed that clopidogrel is an inactive prodrug. After being absorbed into the blood, it needs to rely on an enzyme in the liver, that is, CYP2C19. Only with active metabolites can the clinical efficacy of antiplatelet be exerted. The CYP2C19 enzyme, as a protein, is synthesized under the guidance of the CYP2C19 gene. More and more ...

AI Technical Summary

Problems solved by technology

[0020] (1) When the genotype of the PON1 gene is homozygous for the mutation, no matter what the genotype of the ABCB1 gene is, it is considered that the ability of the patient to convert clopidogrel into the active product is weakened, and the risk of clopidogrel resistance is high;

[0021] (2) When the genotype of the PON1 gene is wild homozygous or mutant heterozygous, no matter what the genotype of the ABCB1 gene is, it is considered that the patient's ability to convert clopidogrel into the active product is slightly weaker, and there is moderate clopidogrel resistance risk;

[0030] At present, almost all laboratory departments of medical institutions, pharmaceutical genetic testing laboratories or other professional testing institutions are manually filling in the report form of clopidogrel drug-related genetic testing, that is, according to the relevant information on the genetic testing instrument. For the results of the genotype of the gene, it is time-consuming and labor-intensive to fill in the items in the report one by one

In addition, because the clopidogrel drug-related gene test report contains many and comprehensive items, including basic patient information, test results, test conclusions, individualized drug recommendations, etc., it also contains test conclusions and a large section of individual In addition, in the case of a large number of test cases, it is cumbersome to issue a test report for clopidogrel drug-related genes based on the genotype results of the relevant genes (CYP2C19, PON1 and ABCB1 genes) on the genetic testing instrument. It is very error-prone, causing errors in the report form, and may even cause clinical drug risks

Images